Physician profile
Brian J Bezack
NPI 1407021850
$4,395.12
in general payments reported to CMS, 2019-2025
13 companies · $731 in 2025
The $731 reported for 2025 was more than what 83% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $333 · 2021: $542 · 2022: $581 · 2023: $1,027 · 2024: $685 · 2025: $731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,439 · Education: $2.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,439.16 |
| Education | $2.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,653.89 | 2019-2025 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $954.03 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $832.60 | 2019-2025 | Nucala |
| Genzyme Corporation | $366.23 | 2019-2025 | |
| Amgen INC. | $205.26 | 2022-2025 | Tezspire |
| Alk-Abello, INC | $168.75 | 2023-2025 | Odactra, Ragwitek, Grastek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.04 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $41.88 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $37.13 | 2022-2023 | Airduo Digihaler |
| Phadia US INC. | $23.97 | 2022 | |
| Merck Sharp & Dohme LLC | $22.89 | 2019 | |
| Circassia INC. | $17.99 | 2020 | |
| Azurity Pharmaceuticals, INC. | $16.46 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bezack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.